GSK 3352589

Drug Profile

GSK 3352589

Alternative Names: GSK-3352589

Latest Information Update: 01 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 22 May 2017 Phase-I clinical trials in Undefined indication (In volunteers) in Australia (PO) (NCT03154086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top